Skip to content

OUTLOOK THERAPEUTICS, INC.: 10-Q filed 2026-02-17

What OUTLOOK THERAPEUTICS, INC. reported in its quarterly report filed 2026-02-17 (fiscal Q1 2026): 35 published measures, 72 facts as tagged in accession 0001104659-26-016554.

This filing

Form
10-Q (quarterly report)
Filed
2026-02-17
Fiscal period
fiscal Q1 2026
Accession
0001104659-26-016554 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All OUTLOOK THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-12-3118,238,574USD
At 2025-09-3018,584,183USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-12-3156,788,039USD
At 2025-09-3050,771,844USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-12-31-38,549,465USD
At 2025-09-30-32,187,661USD
At 2024-12-31-50,290,434USD
At 2024-09-30-73,076,510USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-12-318,677,424USD
At 2025-09-308,083,085USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-23,058,135USD92
2024-10-01 to 2024-12-3117,377,614USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-14,939,111USD92
2024-10-01 to 2024-12-31-10,967,335USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-10-01 to 2025-12-3115,533,450USD92
2024-10-01 to 2024-12-311,742,373USD92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-12-31-628,767,898USD
At 2025-09-30-605,709,763USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-10-01 to 2025-12-3160,205,035shares92
2024-10-01 to 2024-12-3124,233,957shares92

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-10-01 to 2025-12-3160,205,035shares92
2024-10-01 to 2024-12-3124,233,957shares92

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-0.38USD/shares92
2024-10-01 to 2024-12-310.72USD/shares92

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-0.38USD/shares92
2024-10-01 to 2024-12-310.72USD/shares92

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-10-01 to 2025-12-31881,150USD92
2024-10-01 to 2024-12-313,672,420USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-13,483,952USD92
2024-10-01 to 2024-12-31-21,606,852USD92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-12-3117,166,501USD
At 2025-09-3017,388,969USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-12-3149,055,800USD
At 2025-09-3045,814,605USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-12-317,318,649USD
At 2025-09-3010,192,388USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-12-31114,609USD
At 2025-09-301,490,931USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-12-313,458,064USD
At 2025-09-303,338,404USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-1,237,459USD92

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-10-01 to 2025-12-318,612,141USD92
2024-10-01 to 2024-12-3111,946,702USD92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-10-01 to 2025-12-313,634,352USD92
2024-10-01 to 2024-12-319,660,150USD92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-12-3164,556,570shares
At 2025-09-3053,887,233shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-12-318,677,424USD
At 2025-09-308,083,085USD
At 2024-12-315,702,576USD
At 2024-09-3014,927,538USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-12-31212,413USD
At 2025-09-30225,508USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-12-31233,113USD
At 2025-09-30247,698USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-12-31346,111USD
At 2025-09-30417,523USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-12-314,714,026USD
At 2025-09-305,314,320USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-12-314,916,404USD
At 2025-09-304,476,549USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-23,058,135USD92
2024-10-01 to 2024-12-3117,377,614USD92

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-10-01 to 2025-12-3114,931,536USD92
2024-10-01 to 2024-12-311,742,373USD92

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2025-10-01 to 2025-12-3119,484USD92
2024-10-01 to 2024-12-3119,329USD92

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-1,376,322USD92

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-10-01 to 2025-12-31119,660USD92
2024-10-01 to 2024-12-313,109,397USD92

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-2,873,739USD92
2024-10-01 to 2024-12-314,224,022USD92

Inspect the source

Entity
OUTLOOK THERAPEUTICS, INC. / CIK 0001649989
Captured
2026-09-21T17:23:24.422Z
SEC response SHA-256
ce697e8c1ac203fe6827508f0d6a14f8a445ce42f9c031026a98c3f5635933f0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001649989.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))